A prospective, randomized, open label clinical trial of Saroglitazar in patients with NASH
Latest Information Update: 01 Jan 2024
At a glance
- Drugs Saroglitazar (Primary) ; Vitamin E (Primary)
- Indications Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis
- Focus Therapeutic Use
Most Recent Events
- 01 Jan 2024 New trial record
- 14 Nov 2023 Results assessing efficacy of saroglitazaar alone versus its combination with vitamin E in patients with NASH presented at The Liver Meeting 2023: 74th Annual Meeting of the American Association for the Study of Liver Diseases